Primary information |
---|
ID | antitb_1779, |
Name | 17547385 |
N-Terminal modification | Peptide-23 |
C-Terminal Modification | GF-Tic-Oic-GK-Tic-Oic-GF-Tic-Oic-GK-Tic-KKKK |
Chemical Modification | Acetylation |
Linear/Cyclic | Amidation |
Length | Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid |
Chirality | Linear |
Nature | 19 |
Source | L |
Origin | Amphipathic, Hydrophobic |
Species | Synthetic |
Inhibition Concentration | Mycobacterium ranae |
In Vitro/ In vivo | Mycobacterium ranae (ATCC 110) |
Cell Line | MIC = 10 µM or 24 µg/mL |
Inhibition Concentration | Both |
Sequence | 2007 |
Cytotoxicity | RBC |
In vivo Model | NA |
Lethal Dose | 14 % hemolytic activity at 100 µM peptide |
Immune Responce | mouse skin wound healing model |
Mechanism of Action | Acute toxicity was observed at dose of 125 mg/kg |
Target | Stimulate innate immune system |
Combination Therapy | NA |
Other activities | NA |
PMID | NA |
Year of Publication | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) |
Tertiary Structure (Technique) | Not Predicted), |
Primary information |
---|
ID | antitb_1780, |
Name | 17547385 |
N-Terminal modification | Peptide-24 |
C-Terminal Modification | GF-Tic-Oic-GK-Tic-Oic-GF-Tic-Oic-GK-Tic-KKKK |
Chemical Modification | Acetylation |
Linear/Cyclic | Addition of -CONH-CH2-CH2-NH2 |
Length | Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid |
Chirality | Linear |
Nature | 19 |
Source | L |
Origin | Amphipathic, Hydrophobic |
Species | Synthetic |
Inhibition Concentration | Mycobacterium ranae |
In Vitro/ In vivo | Mycobacterium ranae (ATCC 110) |
Cell Line | MIC = 10 µM or 25 µg/mL |
Inhibition Concentration | Both |
Sequence | 2007 |
Cytotoxicity | NA |
In vivo Model | NA |
Lethal Dose | Not tested |
Immune Responce | NA |
Mechanism of Action | NA |
Target | Stimulate innate immune system |
Combination Therapy | NA |
Other activities | NA |
PMID | NA |
Year of Publication | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) |
Tertiary Structure (Technique) | Not Predicted), |
Primary information |
---|
ID | antitb_1781, |
Name | 17547385 |
N-Terminal modification | Peptide-25 |
C-Terminal Modification | GF-Tic-Oic-GK-Tic-Oic-GF-Tic-Oic-GK-Tic-KKKK |
Chemical Modification | Acetylation |
Linear/Cyclic | Addition of CONH-CH2-CH2-CH2-NH2 |
Length | Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid |
Chirality | Linear |
Nature | 19 |
Source | L |
Origin | Amphipathic, Hydrophobic |
Species | Synthetic |
Inhibition Concentration | Mycobacterium ranae |
In Vitro/ In vivo | Mycobacterium ranae (ATCC 110) |
Cell Line | MIC = 10 µM or 25 µg/mL |
Inhibition Concentration | Both |
Sequence | 2007 |
Cytotoxicity | NA |
In vivo Model | NA |
Lethal Dose | Not tested |
Immune Responce | NA |
Mechanism of Action | NA |
Target | Stimulate innate immune system |
Combination Therapy | NA |
Other activities | NA |
PMID | NA |
Year of Publication | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) |
Tertiary Structure (Technique) | Not Predicted), |
Primary information |
---|
ID | antitb_1782, |
Name | 17547385 |
N-Terminal modification | Peptide-26 |
C-Terminal Modification | GF-Tic-Oic-GK-Tic-Oic-GF-Tic-Oic-GK-Tic-KKKK |
Chemical Modification | Free |
Linear/Cyclic | Amidation |
Length | Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid |
Chirality | Linear |
Nature | 19 |
Source | L |
Origin | Amphipathic, Hydrophobic |
Species | Synthetic |
Inhibition Concentration | Mycobacterium ranae |
In Vitro/ In vivo | Mycobacterium ranae (ATCC 110) |
Cell Line | MIC = 10 µM or 24 µg/mL |
Inhibition Concentration | Both |
Sequence | 2007 |
Cytotoxicity | RBC |
In vivo Model | NA |
Lethal Dose | 33.4 % and 14.3% hemolytic activity at 100 µM and 25 µM peptide respectively |
Immune Responce | NA |
Mechanism of Action | NA |
Target | Stimulate innate immune system |
Combination Therapy | NA |
Other activities | NA |
PMID | NA |
Year of Publication | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) |
Tertiary Structure (Technique) | Not Predicted), |
Primary information |
---|
ID | antitb_1800, |
Name | 17547385 |
N-Terminal modification | Peptide-44 |
C-Terminal Modification | GF-Tic-Oic-GK-Tic-Oic-GF-Tic-Oic-GK-Tic-KKKK |
Chemical Modification | Biotinylation |
Linear/Cyclic | Amidation |
Length | Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid |
Chirality | Linear |
Nature | 19 |
Source | L |
Origin | Amphipathic, Hydrophobic |
Species | Synthetic |
Inhibition Concentration | Mycobacterium ranae |
In Vitro/ In vivo | Mycobacterium ranae (ATCC 110) |
Cell Line | MIC = 10 µM or 26 µg/mL |
Inhibition Concentration | Both |
Sequence | 2007 |
Cytotoxicity | NA |
In vivo Model | NA |
Lethal Dose | Not tested |
Immune Responce | NA |
Mechanism of Action | NA |
Target | Stimulate innate immune system |
Combination Therapy | NA |
Other activities | NA |
PMID | NA |
Year of Publication | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) |
Tertiary Structure (Technique) | Not Predicted), |